U.S., Jan. 18 -- ClinicalTrials.gov registry received information related to the study (NCT03801369) titled 'Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer' on Jan. 9.
Brief Summary: This phase II study assesses the efficacy of the combination of olaparib and durvalumab in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olabparib may stop growth of tumors cells by inhibiting some of the enzymes (ADP ribose polymerase (PARP)) needed for cell growth. Durvalumab, a monoclonal antibody, inhibits the growth and spread of tumors by stimulating the patient's antitumor immune response. Giving olaparib and durvalumab together may provide an effective method to treat patients w...